The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.
Respir Res
; 21(1): 178, 2020 Jul 11.
Article
em En
| MEDLINE
| ID: mdl-32653040
ABSTRACT
Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Controle de Qualidade
/
Vacina BCG
/
Infecções por Coronavirus
/
Pandemias
Tipo de estudo:
Health_economic_evaluation
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Respir Res
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Brasil